Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R.

British journal of clinical pharmacology - 1 Jun 2022

Cupido Arjen J, Asselbergs Folkert W, Natarajan Pradeep, Ridker Paul M, Hovingh G Kees, Schmidt A Floriaan

Abstract excerpt

AIMS: Chronic inflammation is a risk factor for cardiovascular disease (CVD). IL-6 signalling perturbation through IL-6 or IL-6R blockade may have potential benefit on cardiovascular risk. It is unknown whether targeting either IL-6 or IL-6 receptor may result in similar effects on CVD and adverse events. We compared the anticipated effects of targeting IL-6 and IL-6 receptor on cardiometabolic risk and potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arthritis, Rheumatoid
Share to Atrial Fibrillation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Coronary Artery Disease

Share to Diabetes Mellitus, Type 2

Share to Interleukin-6

Share to Ischemic Stroke

Share to Mendelian Randomization Analysis

Share to Receptors, Interleukin-6

Source

Open in PubMed Open full text

Identifiers

PMID: 34931349
DOI: 10.1111/bcp.15191
PMCID: PMC9303316

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dissecting the IL-6 pathway in cardiometabolic disease: A Mendelian randomization study on both IL6 and IL6R.PMID 34931349Read ↗

IL6 genetic perturbation mimicking IL-6 inhibition is associated with lower cardiometabolic riskSemantic proximity Read ↗

Interleukin-6 signaling effects on ischemic stroke and other cardiovascular outcomes: a Mendelian Randomization studySemantic proximity Read ↗

Genetically downregulated interleukin-6 signaling is associated with a favorable cardiometabolic profile: a phenome-wide association studySemantic proximity Read ↗

Leveraging genetic data to investigate the effects of interleukin‐6 receptor signalling on levels of 40 circulating cytokinesSemantic proximity Read ↗

Leveraging genetic data to investigate the effects of interleukin-6 receptor signalling on levels of 40 circulating cytokines.Semantic proximity Read ↗

Proteogenomic integration reveals CXCL10 as a potentially downstream causal mediator for IL-6 signaling on atherosclerosisSemantic proximity Read ↗

Exploring the therapeutic potential of interleukin-6 receptor blockade in cardiovascular disease treatment through Mendelian randomization.Semantic proximity Read ↗

Proteogenomic Data Integration Reveals CXCL10 as a Potentially Downstream Causal Mediator for IL-6 Signaling on AtherosclerosisSemantic proximity Read ↗

Genetically proxied IL-6 signaling inhibition, lipoprotein(a) levels, and atherosclerotic disease risk.Semantic proximity Read ↗

A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevitySemantic proximity Read ↗

Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.Semantic proximity Read ↗

Pathway-Based Mendelian Randomization for Pre-Infection IL-6 Levels Highlights Its Role in Coronavirus Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.